The Journal is one of the most valued sources of information for orthopaedists and orthopaedic researchers. Standards of excellence for the content we publish and the customer service that we provide are not going to change. However, the way in which people access content is changing rapidly. Today, content producers are faced with the challenge of providing their content through media that are accessible on-the-go.
Hence, the JBJSmedia YouTube channel. Here you’ll find information about JBJS products, procedure demonstrations, and webinars featuring top experts in the field— easily digestible and accessible on-the-go. You can easily find the videos you are looking for by going to the playlists tab.
The newest feature of our YouTube channel is the JBJS Podcast. These digital audio abstracts of specially selected JBJS articles are overlaid onto a video track and uploaded to the channel at the end of each month.
Social Media and Analytics Specialist, JBJS
Every month, JBJS publishes a Specialty Update—a review of the most pertinent and impactful studies published in the orthopaedic literature during the previous year in 13 subspecialties. Click here for a collection of all OrthoBuzz Specialty Update summaries.
This month, Arvind Nana, MD, co-author of the July 20, 2016 Specialty Update on musculoskeletal infection, selected the three most compelling discoveries from among the more than 100 studies cited in the Specialty Update, which focused on biofilms.
Dr. Nana and his co-authors provide a concise primer on the biology of biofilms, the network of microorganisms that adhere to implant surfaces and form a complex structure surrounded by a self-generated extracellular polymeric matrix. This matrix not only anchors bacteria to orthopaedic implants, but also provides a nearly impenetrable defense mechanism against the host immune system. Staphylococci are the most common biofilm-forming bacteria found in orthopaedics.
Persister Cells in Biofilms
So-called persister cells have an inherent tolerance to antimicrobial agents. Misconceptions about persisters have permeated the literature. The authors provide clarification about persisters:
- Persister cells CAN be reliably killed when the antimicrobial concentration is high enough. The minimum biofilm eradication concentration (MBEC) is lower when antimicrobial exposure is continuous and prolonged.1
- Decreasing the number of microorganisms with antimicrobial intervention is NOT good enough. Cure requires the total elimination of all viable microbes.
Biofilm in Orthopaedic Trauma
Biofilm formation in the setting of open fractures is concerning because biofilm can develop on bone and in soft tissues in a matter of hours. The assumption is that appropriate surgical techniques for open fractures, including therapeutic antibiotic administration, can decrease bioburden and provide fracture stability, thus modulating the acute, local inflammatory response and minimizing biofilm formation.2 However, current technology does not enable noninvasive quantification of biofilm activity and presence in a stable open fracture following wound closure.
Biofilm in Total Joint Arthroplasty
Traditionally, prosthesis-related biofilm infections in the US have been treated by a 2-stage exchange arthroplasty. Although biofilm from the implant is removed by extraction of the components, the potential exists for persistence of biofilm in the surrounding soft tissues. Most patients treated for periprosthetic joint infections also receive intravenous antibiotics, but a recent in vitro study demonstrated that administering cefazolin even at increased concentrations still resulted in persistent Staphylococcus biofilm on cobalt-chromium, polymethylmethacrylate, and polyethylene,3 which supports the need for explantation.
There is still room to develop novel treatment methods for eradicating biofilm in periprosthetic joint infections. Future novel treatment methods for eradicating implant biofilm will help minimize the morbidity associated with current accepted periprosthetic joint infection treatment options.
- Castaneda P, McLaren A, Tavaziva G, Overstreet D. Biofilm antimicrobial susceptibility increases with antimicrobial exposure time. Clin Orthop Relat Res. 2016 Jan 21.
- Pfeifer R, Darwiche S, Kohut L, Billiar TR, Pape HC. Cumulative effects of bone and soft tissue injury on systemic inflammation: a pilot study. Clin Orthop Relat Res. 2013 Sep;471(9):2815-21.
- Urish KL, DeMuth PW, Kwan BW, Craft DW, Ma D, Haider H, Tuan RS, Wood TK, Davis CM 3rd..Antibiotic-tolerant Staphylococcus aureus biofilm persists on arthroplasty materials. Clin Orthop Relat Res.2016 Feb 1.
The Choosing Wisely campaign seeks to bring more awareness to tests and procedures that should be discussed between physicians and patients. The campaign was spearheaded by the ABIM Foundation, and the American Academy of Orthopaedic Surgeons (AAOS) partnered with the campaign to develop a list of the five things physicians and patients should question.
- Avoid performing routine post-operative deep vein thrombosis ultrasonography screening in patients who undergo elective hip or knee arthroplasty.
- Don’t use needle lavage to treat patients with symptomatic osteoarthritis of the knee for long-term relief.
- Don’t use glucosamine and chondroitin to treat patients with symptomatic osteoarthritis of the knee.
- Don’t use lateral wedge insoles to treat patients with symptomatic medial compartment osteoarthritis of the knee.
- Don’t use post-operative splinting of the wrist after carpal tunnel release for long-term relief.
The list was developed after review of approved clinical practice guidelines and included input from specialty society leaders.
This week Mady Tissenbaum retires from her role as Publisher of The Journal of Bone & Joint Surgery. Mady walked through the doors of the JBJS office 42 years ago to assume the role of a copy editor. She has been with JBJS ever since and her career responsibilities developed as the organization grew and expanded. Mady has presided over multiple important changes at JBJS: the move to Needham with the purchase of our building when we outgrew the shared space with The New England Journal of Medicine, the transition from paper and typewriter manuscripts and paper review processes to electronic submission and review, the launch of The Journal online at jbjs.org, and the branching out of our offerings to include JBJS Case Connector, JBJS Essential Surgical Techniques and JBJS Reviews.
Mady has literally “done it all” at JBJS. She has trained and collaborated with 6 Editors and attended over 60 Trustee meetings. She has led countless staff meetings and presented at a similar number of Editorial Board meetings. She has run the HR services, done all the contracting for purchased services and knows every stage of development of our complex IT backbone.
In addition, she is the archivist for The Journal and has most of its history in her head. Throughout her career, she has committed herself to the legacy of quality content that JBJS is known for, as well as to the staff, authors, and readers. Her contributions have enhanced not only JBJS, but also the larger community of scholarly publishing.
We wish you Godspeed in retirement, Mady, and thank you from the bottom of our hearts for dedicating your career to JBJS and the physicians and patients it serves.
Fondly and with great respect,
Marc Swiontkowski, MD
Healthcare spending in 2013 grew at the slowest rate since 1960, according to a recent article in Modern Healthcare. According to federal data, the nation spent $2.9 trillion on healthcare last year, which was an increase of 3.6% from the prior year—and the weakest spending growth since 1960. Reasons cited for the slowdown include aftermath from the Great Recession, changes in health benefits, and federal healthcare spending rollbacks triggered by the Affordable Care Act. For example, Medicare spending increased in 2013 by 3.4%, down from 4% growth in 2012. Spending on technology and construction to upgrade or expand healthcare services dropped during the recession and still has not rebounded. Most analysts don’t expect this growth slowdown to carry into 2014, although quarterly national estimates for 2014 suggest spending growth below 4%. While some of the slowdown in healthcare spending growth may be attributed to doctors and other healthcare professionals running more efficient practices, health spending in 2013 still consumed 17.4% of the US gross domestic product.
The latest market report from Transparency Market Research predicts that the global orthobiologics market will grow at a compound annual rate of nearly 6% over the next 5 years. In 2012, the orthobiologics market was worth $3.7 billion, and it is expected to hit $5.5 billion by the end of 2019. What will drive the growth? The 50+ population is expected to almost double by 2020, and increases in obesity and sports injuries will spur market growth. Technical improvements and a trend away from the use of autografts and allografts will also drive interest in orthobiologics.
JBJS is pleased to be partnering with INSIGHTS Orthopedics, featuring our online content within the new version of their app for iPad. INSIGHTS Orthopedics allows you to create your own personalized medical magazine from conveniently aggregated content, as well as follow what your peers, orthopaedic leaders, and leading Journal Clubs are reading. The newly launched Version 2.0 offers quicker access to relevant content through Featured Articles and reading recommendations.
Learn more about Insights Orthopedics, and download the free app, at http://www.insights.md/orthopedics/
Read the review on Top Ortho Apps at http://toporthoapps.com/2013/08/31/insights-orthopedics/
Thomas Thornhill, MD is the John B and Buckminster Brown Professor of Orthopaedic Surgery at Harvard Medical School and Chair of the Department of Orthopaedics at Brigham and Women’s Hospital in Boston. He recently was kind enough to answer a few questions for OrthoBuzz.
JBJS: What are some of the most significant changes in orthopaedics you have observed during your career?
Dr. Thornhill: The quality of applicants to orthopaedic residency programs seems to improve every year. I think anyone involved today in choosing new residents feels that he or she would never have been chosen by contemporary standards. Moreover, our profession has become more diverse, which is a good thing. Our residency/fellowship program has a significant number of women and underserved minorities. The most impressive thing is that there is a single set of criteria for all applicants, giving us a uniformly outstanding resident pool.
Also, the emerging use of biologics has enhanced our ability to care for some common and uncommon musculoskeletal problems. For example, the use of disease-modifying anti-rheumatic drugs (DMARDs) has revolutionized the care of the rheumatoid patient. When I began practice, 80 percent of patients undergoing total joint arthroplasty had rheumatoid arthritis, and now it is only approximately 10 percent in a center well-known for treating the rheumatoid patient.
Third, I’ve seen significant changes in the globalization of orthopaedics. The internet and social media have improved global communication. Many of the meetings in arthroplasty are global in their scope, and we are learning a tremendous amount from our orthopaedic colleagues around the world.
JBJS: Brigham and Women’s Hospital is recognized as a leader in providing patient-centered, team-based care. Why is this approach so important to orthopaedic patients?
Dr. Thornhill: Brigham and Women’s Hospital does not exist in a vacuum, and the Boston area has many fine academic and community hospitals with strong orthopaedic programs. Each subscribes to the concept of providing the right care, at the right place, and at the right time. Moreover, the changes in healthcare systems in Massachusetts and throughout the United Sates require each of us to be innovative. In the past, clinical surpluses could be used for educational and research program funding, but with the shrinking healthcare economy, there are many essential, but non-remunerative programs that are in jeopardy. Efficient, team-based care is one way to ensure we have the resources to continue these important educational and research programs. Finally, the switch from fee-for-service to episode-of-care reimbursement and population health is going to require each of us to adjust to inevitable changes in healthcare. In this environment, patient-centered, team-based care makes the most sense to ensure optimal outcomes.
JBJS: Orthopaedists are increasingly focused by subspecialty. What do you see as the benefits and risks of increased subspecialization within orthopaedics?
Dr. Thornhill: We are indeed becoming more and more subspecialized. One benefit is that it will certainly improve expertise in these areas, where patient demand is growing in an exponential fashion. It will also allow specialists to remain current in their subspecialty and prompt innovation in these different fields of orthopaedic practice.
On the other hand, intensive subspecialization may prevent us from “thinking outside the box.” Communication and idea crossover are important, and while we know many of the leaders in our own subspecialty, we don’t know many in other areas. Most of the meetings now are subspecialty-driven and fail to benefit from sharing of ideas with other subspecialties. Our graduates now virtually all take a fellowship, and 15 percent of them take two fellowships. One could argue that a trauma surgeon or musculoskeletal oncologist should have arthroplasty experience because there is a good deal of overlap within these disciplines. We should also remember that lessons learned in one specialty may benefit another. For instance, hip surgeons have long considered neck shaft angle, offset, and even material properties that have now been incorporated into the design and implantation of shoulder prostheses.
JBJS: How do you think JBJS can best address the needs of the orthopaedic community in light of this increasing subspecialization?
Dr. Thornhill: JBJS needs to maintain its preeminence as the leading orthopaedic journal. To do so, it must remain relevant, explore other mechanisms in addition to a printed version to transmit information, and the articles must remain balanced throughout the various subspecialties. I think JBJS has done an outstanding job moving into electronic media. One concern is the economics of maintaining The Journal’s viability and the concerns of some young authors about the cost of submitting a manuscript.
JBJS: Looking ahead to the next 20 years or so, what three significant advances or changes in orthopaedics do you foresee?
Dr. Thornhill: To paraphrase the book Future Shock, “If you want to see what is in the future, look around because it is happening somewhere now.” I think there will be an increased use of biologics in applications such as induction of bone formation, cartilage repair, tissue engineering, and the use of stem cells for repairing and regenerating musculoskeletal structures.
Also, we will look back several years from now and laugh at the materials we currently use for total joint replacement. One important concern in my area of interest is that 15 to 20 percent of patients undergoing total knee replacement are not completely satisfied, while many people with total hips and total shoulders forget they had an implant. I think the cause is multifactorial, but I do think that we will develop or engineer materials with characteristics that will improve the kinematics of knee prostheses, and hopefully our patients will feel that their knee replacements are more normal.
Finally, there will be an increase in technology, manufacturing, and research and development on a global scale. Global cooperation and time zone differences can allow manufacturing, design, and outcome studies to occur 24-7 in a more cost-effective fashion. If we also foster the interactions between academia and industry in a controlled fashion, we will further appreciate the tremendous advances in our specialty due to these relationships.
JBJS: What is your favorite thing about your profession?
Dr. Thornhill: The hackneyed phrase is that we get instant gratification from pain relief and restoration of function in our patients. While this is true, when I trace my training from internal medicine to orthopaedics, I recall drawing a Venn diagram showing that the three things I liked the best were surgery, rheumatology, and neurology. The only true intersection among those is orthopaedics. I would say that other than my family, I appreciate my interactions with students, residents, fellows, and colleagues, and I thoroughly enjoy treating my patients as people. Finally, I like the operating room and the technical aspects of orthopaedics.
JBJS: Thank you, Dr. Thornhill, for your time.
Kent Anderson, CEO/Publisher of the JBJS Special Report: “It Takes a Team”, sits down and talks about the 2013 Boston Marathon Bombings. Some of the topics that Kent discusses in the interview are the emphasis on teamwork in healthcare, the importance of the first responders and orthopaedic surgeons who treated the survivors and lessons learned from this horrific tragedy. Listen now: http://bit.jbjs.org/1ph87Hu
Up against an April 1 deadline that would see Medicare payments to physicians plunge by nearly 24%, a bipartisan group of Congressional negotiators introduced legislation that would repeal Medicare’s sustainable growth rate (SGR) formula and replace it with an annual 0.5% pay increase for five years. The proposed legislation contains additional provisions designed to transition Medicare from a pay-per-procedure system to one that promotes value through alternative payment methods (APMs) and rewards physicians for engaging with APMs. Those provisions include:
- A consolidation of three existing Medicare quality programs into one
- Incentives for care coordination
- Involvement by physicians in developing clinical guidelines, performance measures, and APMs
- Making provider-specific quality and utilization data more publicly accessible
Before we hail this as the epitome of bipartisan success, it should be noted that the legislation in its current form does not detail how Congress would pay for a permanent SGR repeal, which is estimated to cost between $120 billion and $150 billion. That significant detail will be debated if and when the full membership of both chambers considers the bill. Congress has been at similar SGR crossroads before and ended up passing short-term “patches” without permanently revising what everyone agrees is a failed formula.